Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
1. To compare the efficacy of tofacitinib at doses of 5 mg BID and 10 mg BID versus placebo for the treatment of rheumatological signs and symptoms of PsA, in subjects with active PsA who have had an inadequate response to a traditional non biologic Disease Modifying Anti Rheumatic Drug (DMARD). 2. To compare physical function status of subjects with active PsA who have had an inadequate response to a traditional non biologic Disease Modifying Anti Rheumatic Drug (DMARD) after administration of tofacitinib at doses of 5 mg BID and 10 mg BID versus placebo. 3. To compare the safety and tolerability of two doses (5 mg BID and 10 mg BID) of tofacitinib versus placebo in subjects with active PsA who have had an inadequate response to a traditional non biologic Disease Modifying Anti Rheumatic Drug (DMARD).
Critère d'inclusion
- Psoriatic arthritis (PsA)